Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Single Ascending Doses of BIIB063 in Healthy Volunteers

17. april 2017 opdateret af: Biogen

Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy volunteers. The secondary objectives of the study are to estimate the PK parameters of single ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F) of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses of BIIB063.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

29

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 55 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  • All male subjects and all female subjects of childbearing potential must practice at least 1 highly effective method of contraception (i.e., contraceptive measure with a failure rate of <1% per year; estrogen-containing contraceptives are prohibited) during the study and be willing and able to continue contraception for 4 months after being dosed with study treatment. Male subjects must also be willing to refrain from sperm donation for at least 4 months after the last dose of study treatment. Male subjects must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study.
  • Must have a body mass index between 18 and 30 kg/m2, inclusive.
  • Must be in good health as determined by the Investigator, based on medical history, physical examination, and 12-lead ECG.

Key Exclusion Criteria:

  • History of or positive test result at screening for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
  • History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
  • Personal or family history of cardiovascular disease under the age of 50 years, inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency), or anti-phospholipid Ab syndrome (APS).
  • History of meningococcal vaccination or meningococcal meningitis, or history of hypersensitivity to single components of meningococcal vaccines (including MENVEO), any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.
  • History of tuberculosis (TB) or positive QuantiFERON®-TB Gold test
  • Personal history of thromboembolic events
  • Treatment with any prescription or over-the-counter medication within 14 days prior to randomization (excluding vitamins, dietary supplements, herbal preparations, progestin-only birth control, and paracetamol up to 4 g/day for no more than 5 consecutive days).
  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months
  • Current enrollment or a plan to enroll in any other drug, biologic or device clinical study, or treatment with an investigational drug or approved therapy for investigational use within 3 months
  • Blood donation (1 unit or more) within 3 months prior to randomization.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: IV Dose 1
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkelt dosis
Eksperimentel: IV Dose 2
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkelt dosis
Eksperimentel: IV Dose 3
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkelt dosis
Eksperimentel: IV Dose 4
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkelt dosis
Eksperimentel: IV Dose 5
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkelt dosis
Eksperimentel: IV Dose 6
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkelt dosis
Eksperimentel: IV Dose 7
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
Enkelt dosis
Eksperimentel: SC Dose
Single SC dose or matching placebo
Single ascending IV dose
Enkelt dosis

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: Up to week 12
Up to week 12
Number of participants with clinically significant laboratory assessment abnormalities
Tidsramme: Up to week 12
Up to week 12
Number of participants with clinically significant Vital sign abnormalities
Tidsramme: Up to week 12
Up to week 12
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Tidsramme: Up to week 12
Up to week 12
Number of participants with clinically significant physical examination abnormalities
Tidsramme: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for tetanus
Tidsramme: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for diphtheria
Tidsramme: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for pneumococcus
Tidsramme: Up to week 12
Up to week 12

Sekundære resultatmål

Resultatmål
Tidsramme
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)
Tidsramme: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)
Tidsramme: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)
Tidsramme: Up to week 12
Up to week 12
Number of participants with positive serum anti-BIIB063 antibodies
Tidsramme: Up to week 12
Up to week 12
Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063
Tidsramme: Up to 12 weeks
Up to 12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. september 2015

Primær færdiggørelse (Faktiske)

1. juni 2016

Studieafslutning (Faktiske)

1. juni 2016

Datoer for studieregistrering

Først indsendt

27. august 2015

Først indsendt, der opfyldte QC-kriterier

17. september 2015

Først opslået (Skøn)

21. september 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. april 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. april 2017

Sidst verificeret

1. april 2017

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 234HV101
  • 2015-001283-18 (EudraCT nummer)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .